Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically documented unresectable Stage III NSCLC that has not progressed following definitive platinum based CRT or extensive disease (Stage IV) SCLC~* ECOG performance status of 0 or 1~* For participants with SCLC: At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 TL at baseline~* Absence of EGFR mutation or ALK rearrangement prior to screening~Exclusion Criteria:~* History of allogeneic organ transplantation~* Autoimmune or inflammatory disorders, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome~* Uncontrolled intercurrent illness~* History of another primary malignancy~* History of active primary immunodeficiency~* Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)~* Brain metastases or spinal cord compression~* Persistent toxicities (CTCAE Grade \>2) caused by previous anticancer therapy, excluding alopecia~* Receipt of live attenuated vaccine within 30 days prior to the first dose of IP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 130 Years
- Healthy Volunteers: f

Study Arms:
- Patients with NSCLC (Type: EXPERIMENTAL): Patients with Non-Small Cell Lung Cancer
- Patients with SCLC (Type: EXPERIMENTAL): Patients with Small Cell Lung Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).